T issue-specific enhancer elements have been mapped for many genes, but remain largely a mystery for genes that are expressed specifically in neurons. Why should this be the case? There is a practical reason: for cells other than neurons, tissuespecific gene expression has been generally studied in transient expression assays, which depend on the transfection of DNA into large numbers of recipient cells (usually established cell lines). These assays quantify the activity of a reporter gene, often encoding an enzyme such as bacterial chloramphenicol acetyltransferase (CAT) 1, whose expression is directed by flanking DNA sequences of the gene being studied. In the past, neurons have been virtually impossible to study in this way: it is difficult to obtain pure populations of neurons in primary culture, especially in sufficient quantity to make transient expression assays worth performing, and neurons are also relatively intractable to DNA transfection. As there are almost no cell lines that represent specific types of neurons, in vitro studies of gene expression that is specific to the nervous system have been limited to genes that are expressed in tumors such as gliomas, neuroblastomas and pheochromacytomas, which occur with reasonable frequency and from which cell lines can be established (for example, see Refs 2, 3).
The alternative to using cell lines is to study tissue-specific gene expression in transgenic mice 4. This approach has advantages and disadvantages: the organism itself does all the necessary tissue controls, but the approach is costly and, more importantly, it is slow. The time from initial egg transfer to tail blot is at least six weeks (this can be reduced to three weeks if polymerase chain reaction techniques are used to detect the presence of the transgene), and it then takes another seven to eight weeks before the next generation can be tested to determine if germ-line transformation has been achieved 5. In contrast, transfection assays of transient gene expression take only a few days.
Immortalized neurons derived from tumors in transgenic mice
Despite the fact that generating a transgenic mouse is a slow process, it might nonetheless offer the most direct route from the identification of a gene that is expressed specifically in a particular type of neuron, to in vitro studies of gene regulation in that cell type. This is because transgenic mice can now be used to generate cell lines from particular types of neurons. In two recent studies 6,7, different groups have used relatively long stretches (approximately 2 kilobases) of 5' flanking DNA sequences from two genes expressed in the nervous system to direct oncogene expression in transgenic mice. In both cases, transgenic mice developed tumors in the appropriate regions of the nervous system and in both cases the investigators have been successful in establishing cultured cell lines with the properties of neurons from these tumors (Fig. 1) .
The use of transgenic mice to target tumorigenesis to a specific cell type was first demonstrated by Hanahan 8. Mice carrying a transgene that consisted of the 5' flanking sequences of the rat insulin II gene fused to the SV40 early region encoding large and small tumor antigens (Tag) specifically expressed Tag in the beta cells of the endocrine pancreas. Tumors developed with a high frequency (1-2% of the islets progressed to tumors) and retained at least one important property of the beta cells: they expressed insulin, so much so that transgenic mice bearing tumors died prematurely of severe hypoglycemia.
Baetge and colleagues used the same strategy to target catecholaminergic cells of the adrenal gland and retina, using 2 kilobases of the 5' flanking region of the human phenylethanolamine N-methyltransferase (PNMT) gene to direct Tag expression in transgenic mice 9. Targeted Tag expression led to the formation of adrenal and eye tumors. In a more recent study 6, they describe the establishment of a neuronal cell line from an eye tumor of one of these transgenic mice. Cultured cells from this tumor (RT-1 cells) have a neuronal morphology (phase-bright cell bodies and extensive processes), and express neuronal proteins such as GAP-43 and all three neurofilament subunits. The cells are also immunoreactive with two monoclonal antibodies that stain amacrine cells of the rat retina, VCI.1 and HPC-1 (Refs 10, 11) . However, RT-1 cells do not express the enzymes that are characteristic of catecholaminergic neurons: tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine biosynthesis, and PNMT, the terminal enzyme in this pathway. The failure of RT-1 cells to express TH is perhaps not surprising; there is a population of PNMT-immunoreactive amacrine cells in the retina that lack detectable TH 12, and these might very well be the cells that were immortalized by the strategy used by Baetge and colleagues.
Lack of PNMT expression is more disturbing, however, since it is presumably the PNMT promotet/enhancer that directs the continuous expression of Tag in these cells. The eye tumors themselves are reported to lack catecholaminergic properties, so the failure of RT-1 cells to express PNMT is probably not a result of culture conditions. One possibility is that the cells immortalized in the eye tumors are not the PNMTexpressing amacrine cells of the retina at all. Ectopic expression of chimeric genes in transgenic mice has been observed, and might be the result of novel expression specificities dictated by the juxtaposition of cis-acfing regulatory sequences from unrelated genes (see Ref. 13) . Alternatively, as the authors suggest, Tag expression might somehow suppress expression of the endogenous PNMT gene. If this is the case, however, suppression must be specific to retinal neurons, since the authors note that adrenal cell lines derived from tumors in the same
